

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Date: 12th September 2023

To,
The Manager
Listing Department
BSE Limited
Bombay Stock Exchange
P.J. Towers, Dalal Street
Mumbai - 400 001.

Ref: Scrip Code 956084 and ISIN INE988W07019

Subject: Submission under Regulation 52(1),52(2), 52(4), 52(7) of Securities Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015.

Dear Sir/Ma'am,

With reference to the subject matter, Please find enclosed the following:

- i. Unaudited Quarterly and Year to date Financial Results for the Quarter ended 31st December 2022 and Limited review report thereon.
- ii. The disclosure of the items as required under Regulation 52(4) of SEBI (LODR), 2015.
- iii. A disclosure under Regulation 54 (2) of SEBI (LODR), 2015.
- iv. Security Cover Certificate under Regulation 56(1)(d) of SEBI (LODR),2015.

Please take the above information on your records.

For Genlink Pharma Solutions Private Limited

Anand Shah
Director
DIN: 00597145



Independent Auditor's Limited Review Report on the Quarterly Unaudited Financial Results of the Company for the quarter ended 31st December, 2022 pursuant to the Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended.

Review Report to

The Board of Directors

Genlink Pharma Solutions Private Limited

Re: Limited Review Report of the Unaudited Financial Results for the quarter ended 31st December, 2022 and year to date from 1st April 2022 to 31st December 2022.

1. We have reviewed the accompanying statement of Unaudited Financial Results of **Genlink Pharma Solutions Private Limited**, ("the Company"), for the quarter ended 31st December, 2022 and year to date from 1st April, 2022 to 31st December, 2022 ("the Statement"), attached herewith being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the regulation') as amended (the "Listing Regulation").
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company, management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India.
4. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



Shankarlal Jain & Associates LLP
Chartered Accountants



12, Engineer Building, 265 Princess Street, Mumbai - 400 002. India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

5. Based on our review, conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**FOR SHANKARLAL JAIN & ASSOCIATES LLP,
CHARTERED ACCOUNTANTS
FIRM REG NO: - 109901W/W100082**

**SATISH JAIN
PARTNER
MEMBERSHIP NO.: 048874
UDIN: 23048874BGTMGJ6592**



Place: Mumbai
Date : 11-09-2023

Shankarlal Jain & Associates LLP

Chartered Accountants



12, Engineer Building, 265 Princess Street, Mumbai - 400 002. India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

To,
Stock Exchange (s)

As per operational circular - SEBI/HO/DDHS/DDHS_Div1/P/CIR/2022/0000000103 dated July 29, 2022 issued by Securities Exchange Board of India (SEBI) requiring to furnish Statement of Assets and Liabilities of the entity, based on examination of books of accounts and other relevant records/documents of **GENLINK PHARMA SOLUTIONS PRIVATE LIMITED**, (CIN: U74110MH2016PTC280765) having its registered office at 1701, 17th Floor, Kesar Solitaire, Plot No 5, Sector 19, Sanpada, Navi Mumbai – 400 705, Maharashtra, India, given below is the Statement of Assets & Liabilities for half year ending on 31st December 2022 which is subject to audit: -

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED			
Statements of Assets And Liabilities			
(Amount in INR)			
Particulars	Note No.	As at 31st Dec 2022 (Unaudited)	As at 31 March 2022 (Audited)
I. ASSETS			
1 Non-current assets			
(a) Property, Plant & Equipment & Intangible Assets	2	2,84,94,394	2,88,97,971
(b) Non-current investments	3	24,89,95,479	24,89,95,479
2 Current assets			
(a) Trade receivables	4	-	-
(b) Cash and cash equivalents	5	16,323	57,43,810
(c) Loans	6	47,02,686	-
(d) Other current assets	7	7,61,688	11,35,056
TOTAL		28,29,70,570	28,47,72,315
II. EQUITY AND LIABILITIES			
1 Equity			
(a) Share capital	8	1,00,000	1,00,000
(b) Reserves & Surplus	9	47,49,146	38,98,695
2 Non-current liabilities			
(a) Financial Liabilities			
(i) Long-term borrowings	10	2,20,22,922	2,21,14,531
3 Current liabilities			
(a) Financial Liabilities			
(i) Trade payables	11	3,11,040	77,576
(ii) Other financial liabilities	12	26,39,479	31,33,753
(b) Short-term borrowings	13	25,27,84,483	25,46,62,881
(b) Current tax liabilities & Provisions	14	3,63,500	2,57,500
(c) Other Current liabilities	15	-	5,27,379
TOTAL		28,29,70,570	28,47,72,315

FOR SHANKARLAL JAIN & ASSOCIATES LLP
CHARTERED ACCOUNTANTS
FIRM REG NO. 109901W/W100082

Jain S.

SATISH JAIN
Partner
Membership No. 048874
UDIN: 23048874BGTMG13249



Place: Mumbai
Date : 11/09/2023

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly Genlink Pharma Investments Private Limited)

CIN No : U74110MH2016PTC280765

Regd Off. Office No - 1701, 17th Floor, Kesar Solitaire, Plot No. 5, Sector 19, Sanpada Navi Mumbai, 400705, Maharashtra, India.

Standalone Unaudited Financial Results for the Quarter ended 31st December, 2022

INR

Sr. No.	Particulars	Three months ended 31/12/2022	Preceding three months ended 30/09/2022	Year to date figures for current period ended 31/12/2022	Previous year ended 31/03/2022
		Unaudited	Unaudited	Unaudited	Audited
		1	Income from Operations		
(i)	Net Sales/Income from Operations (Net of excise duty)	10,89,000	10,89,000	32,67,000	40,92,000
(ii)	Other Income	95,936	1,19,194	3,04,529	5,82,065
	Total Income from Operations	11,84,936	12,08,194	35,71,529	46,74,065
2	Expenses				
(i)	Cost of Material Consumed	-	-	-	-
(ii)	Purchase of Stock in trade	-	-	-	-
(iii)	Change in Inventory of Finished Goods, Work In progress and Stock in trade	-	-	-	-
(iv)	Employee Benefits Expenses	-	-	-	-
(v)	Depreciation and Amortization Expenses	1,35,212	1,35,212	4,03,577	5,11,443
(vi)	Finance Cost	4,90,736	5,11,879	15,24,590	21,65,206
(vii)	Other Expenses	1,87,939	1,95,581	6,00,971	7,80,200
	Total Expenses	8,13,887	8,42,672	25,29,138	34,56,849
3	Profit/(Loss) from operation before tax	3,71,049	3,65,522	10,42,391	12,17,216
4	Tax Expenses	64,022	64,022	1,92,066	1,74,200
5	Profit/(Loss) from ordinary activities for the period	3,07,027	3,01,500	8,50,325	10,43,016
6	Other Comprehensive Income				
(i)	Items that will not be reclassified to profit or loss	-	-	-	-
(ii)	Items that will be reclassified to profit or loss	-	-	-	-
	Total Comprehensive Income/(Loss) for the period	-	-	-	-
7	Paid up Equity Share Capital of 10/- each	1,00,000	1,00,000	1,00,000	1,00,000
8	Earning per Share(not annualised)				
	Basic	30.70	30.15	85.03	104.30
	Diluted				



Date: 11-09-2023
Place: Navi Mumbai

For Genlink Pharma Solutions Private Limited

[Handwritten Signature]

Susheel Koul
Managing Director
DIN: - 00925887
Navi Mumbai
Date :

Anand Shah
Director
DIN: - 00597145
Navi Mumbai
Date :

[Handwritten Mark]

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED
(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)
STANDALONE BALANCE SHEET AS AT 31st December 2022

Particulars	Note No.	(Amount in INR)			
		As at 31st Dec 2022 (Unaudited)	As at 30 Sept 2022 (Unaudited)	As at 30 June 2022 (Unaudited)	As at 31 March 2022 (Audited)
I. ASSETS					
1 Non-current assets					
(a) Property, Plant & Equipment & Intangible Assets	2	2,84,94,394	2,86,29,606	2,87,64,818	2,88,97,971
(b) Non-current investments	3	24,89,95,479	24,89,95,479	24,89,95,479	24,89,95,479
2 Current assets					
(a) Trade receivables	4	-	-	-	-
(b) Cash and cash equivalents	5	16,323	3,393	14,162	57,43,810
(c) Loans	6	47,02,686	50,38,000	53,65,880	57,43,810
(d) Other current assets	7	7,61,688	13,40,827	12,94,735	11,35,056
TOTAL		28,29,70,570	28,40,07,305	28,44,35,073	28,47,72,315
II. EQUITY AND LIABILITIES					
1 Equity					
(a) Share capital	8	1,00,000	1,00,000	1,00,000	1,00,000
(b) Reserves & Surplus	9	47,49,146	44,41,994	41,40,618	38,98,695
2 Non-current liabilities					
(a) Financial Liabilities					
(i) Long-term borrowings	10	2,26,22,922	2,27,62,341	2,34,17,190	2,21,14,531
3 Current liabilities					
(a) Financial Liabilities					
(i) Trade payables	11	3,11,040	1,59,640	81,178	77,576
(ii) Other financial liabilities	12	26,39,479	25,65,264	36,03,870	31,33,753
(b) Short-term borrowings	13	27,84,183	25,27,18,967	25,27,18,967	25,46,62,881
(b) Current tax liabilities & Provisions	14	3,63,500	4,12,751	3,73,250	2,57,500
(c) Other Current liabilities	15	-	8,45,348	-	5,27,373
TOTAL		28,29,70,570	28,40,07,305	28,44,35,073	28,47,72,315



For Genlink Pharma Solutions Private Limited

Anand Shah
Director

DIN: - 00597145

Navi Mumbai

Date: 11-09-23

Sushree Koul

Managing Director

DIN: - 00925857

Navi Mumbai

Date: 11-09-23

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED
(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)
STANDALONE STATEMENT OF PROFIT AND LOSS FOR THE QUARTER ENDING 31st December 2022

Particulars	Refer Note No	As at 31st Dec 2022 (Unaudited)	For the quarter ended 31st Dec 2022 (Unaudited)	For the H1 ended 30 Sept 2022 (Unaudited)	For the quarter ended 30 Sept 2022 (Unaudited)	For the quarter ended 30 June 2022 (Unaudited)	(Amount in INR) For the year ended 31 March 22 (Audited)
I REVENUE							
Revenue from operations	16	32,67,000	10,89,000	21,78,000	10,89,000	10,89,000	40,92,000
Other income	17	3,04,529	95,936	2,08,593	1,19,194	89,399	5,82,065
Total Income		35,71,529	11,84,936	23,86,593	12,08,194	11,78,399	46,74,065
II EXPENSES							
Finance costs							
Depreciation and amortisation expenses	18	15,24,590	4,90,736	10,33,854	5,11,879	5,21,975	21,65,206
Other expenses	19	4,03,577	1,35,212	2,68,365	1,35,212	1,33,153	5,11,443
	20	6,00,971	1,87,939	4,13,032	1,95,581	2,17,326	7,80,200
Total expenses		25,29,138	8,13,887	17,15,251	8,42,672	8,72,454	34,56,849
III Profit/(Loss) before exceptional items and tax (II-III)		10,42,391	3,71,049	6,71,343	3,65,523	3,05,945	12,17,216
IV Exceptional items							
III Profit/(Loss) before tax (I-II)		10,42,391	3,71,049	6,71,343	3,65,523	3,05,945	12,17,216
IV Tax expense							
Current tax		1,92,066	64,022	1,28,044	64,022	64,022	1,89,883
MAT Credit							(2,568)
(Excess)/Short Provision for Tax							(13,116)
V Profit/(Loss) after tax (III-IV)		8,50,325	3,07,027	5,43,299	3,01,501	2,41,922	10,43,016
VI Earnings Per Share							
-Basic & Diluted		85.03	30.70	54.33	30.15	24.19	104.30

For Genlink Pharma Solutions Private Limited



Anand Shah
Director
DIN: - 00597145
Navi Mumbai

Susheel Koul
Managing Director
DIN: - 00925887
Navi Mumbai

Date: 11-09-23 Date: 11-09-23

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED
(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)
STANDALONE CASH FLOW STATEMENT FOR THE QUARTER ENDED 31st December 2022

(Amount in INR)

PARTICULARS	As at 31st Dec 2022 (Unaudited)	As at 31 March 2022 (Audited)
A Cash flow from Operating Activities		
(Loss) / Net profit before Taxation	10,42,391	12,17,216
Adjustment for:		
Interest and Finance Charges	15,24,590	21,65,206
Depreciation and amortisation expenses	4,03,577	5,11,443
Interest Income	(3,03,991)	(5,57,065)
Operating Profit/(Loss) before working capital Changes	26,66,567	33,36,800
Adjustment for:		
Trade Receivables	-	26,254
Short Term Loans and Advances		-
Other Current Assets	3,73,368	32,190
Other Long Liabilities		-
Trade Payable	2,33,464	-
Other Current Liabilities	(10,21,653)	2,95,210
Provisions		-
Cash Generated from/(Used) in Operating Activities	22,51,746	36,90,454
Taxes Paid (net)	(86,066)	(1,92,024)
Net Cash Flow from/(Used) in Operating Activities	21,65,680	34,98,430
B Cash flow from Investing Activities		
Purchase of Fixed assets		
Investments		-
Sale of Fixed assets		
Loan given to Associates	(47,02,686)	
Interest Received	3,03,991	1,33,566
(Purchases)/ Sale of Investments (Net)		
Increase in long term loans & advances		
Net Cash Flow from/(Used) in Investing Activities	(43,98,695)	1,33,566
C Cash flow from Financing Activities		
Dividend and DDT		
(Decrease) / Increase in Long term borrowings	(91,609)	(17,37,572)
Proceeds from Short term borrowings	(18,78,273)	
Interest and Finance Charges	(15,24,590)	(21,65,207)
Net Cash Flow from/(Used) in Financing Activities	(34,94,472)	(39,02,779)
Net Increase/(Decrease) in Cash and Cash equivalents (A+B+C)	(57,27,487)	(2,70,783)
Opening Cash and cash equivalent		
Cash in Hand	67	67
Balance in Current Account	57,43,743	60,14,526
Balance in Fixed deposit Account		
	57,43,810	60,14,593
Closing Cash and cash equivalent		
Cash in Hand	67	67
Balance in Current Account	16,256	57,43,743
Balance in Fixed deposit Account		
	16,323	57,43,810



For Genlink Pharma Solutions Private limited

Anand Shah
Chairman
DIN: - 00597145
Navi Mumbai

Susheel Koul
Managing Director
DIN: - 00925887
Navi Mumbai

Date: 11-09-23 Date: 11-09-23

Q

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

STANDALONE STATEMENT OF CHANGES IN EQUITY FOR PERIOD ENDING 31st December 2022

Particulars	(Amount in INR) As at 31st December 2022 Amount	(Amount in INR) As at 31st March 2022 Amount
A. Equity Share capital		
Opening Balance	1,00,000	1,00,000
Changes in equity share capital during the year	-	-
	1,00,000	1,00,000
B. Other Equity		
Retained Earning		
Opening Balance	38,98,696	28,55,680
Changes in reserves and surplus during the year	8,50,325	10,43,016
Closing Balance	47,49,021	38,98,696



Anand Shah

Anand Shah

Director

DIN: 00597145

Date: 11-09-23

Susheel Koul

Susheel Koul

Managing Director

DIN: 00925887

Date: 11-09-23

9

ENALTEC PHARMA RESEARCH PRIVATE LIMITED
(Formerly Known as Getz Pharma Research Private Limited)

Notes forming part of Financial Statements for the year ended 31st December 2022

Note 2 : PROPERTY, PLANT & EQUIPMENTS

(Amount in INR)

Particulars	Gross Block (at cost)			Depreciation			Net Block		
	As at 01-04-2022	Additions / Adjustments	Sale / Adj	As at 31-12-2022	As at 01-04-2022	For the Period	Deductions/ Adjustments	As at 31-12-2022	As at 31-03-2022
Office Premises	3,06,88,008	-	-	3,06,88,008	17,90,037	4,03,577	-	21,93,614	2,84,94,394
Current Year's Total	3,06,88,008	-	-	3,06,88,008	17,90,037	4,03,577	-	21,93,614	2,84,94,394
Previous Year's Total	3,06,88,008	-	-	3,06,88,008	12,78,594	5,11,443	-	17,90,037	2,88,97,971



GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

STANDALONE STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDING 31st December 2022

Note 1 – SIGNIFICANT ACCOUNTING POLICIES & NOTES TO THE ACCOUNTS

1 PRINCIPAL ACCOUNTING POLICIES

1 Basis of Preparation of Financial Statements:

The financial statements have been prepared on accrual basis under the historical cost convention as a "going concern" (subject to note to schedule 10) and comply in all material aspects with the applicable accounting principles in India, accounting standards notified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014. The accounting policies adopted in the preparation of the financial statements are consistent with those followed in the previous year.

1 Use of Estimates:

The preparation of the financial statements in conformity with AS requires the Management to make estimates and assumptions considered in the reported amounts of assets and liabilities (including contingent liabilities) and the reported income and expenses during the year. The Management believes that the estimates used in preparation of the Financial Statements are prudent and reasonable. Future results could differ due to these estimates and the differences between the actual results and the estimates are recognised in the periods in which the results are known / materialise.

1 Revenue Recognition:

a) Revenue from Services is recognised in accordance with the terms of the contract with customers when the related performance obligation is completed.

b) Interest income is accounted on accrual basis.

1 Property, plant and equipment:

Buildings held for use for administrative purposes, are stated in the Balance Sheet at cost less accumulated depreciation.

Depreciation is recognised so as to write off the cost of assets less their residual values over their useful life, using straight-line method. The estimated useful lives, residual values and depreciation method are reviewed at the end of each reporting period, with the effect of any changes in estimate accounted for on a prospective basis.

2 Taxes on Income:

a) Tax expense comprises both Current Tax and Deferred Tax. Current tax is the amount of tax payable on taxable income for the year as determined in accordance with the applicable tax rates and the provisions of the Income-tax Act, 1961 and other applicable tax laws.

b) Deferred tax is recognised on timing differences, being the differences between the taxable income and the accounting income that originate in one period and are capable of reversal in one or more subsequent periods. Deferred tax is measured using the tax rates and the tax laws enacted or substantively enacted as at the reporting date. Deferred tax liabilities are recognised for all timing differences. Deferred tax assets for timing differences in respect of unabsorbed depreciation, carry forward of losses and items relating to capital losses are recognised only if there is virtual certainty supported by convincing evidence that there will be sufficient future taxable income available to realise such assets. Deferred tax assets are recognised for timing differences of other items only to the extent that reasonable certainty exists that sufficient future taxable income will be available against which these can be realised. Deferred tax assets and liabilities are offset if such items relate to taxes on income levied by the same governing tax laws and the company has a legally enforceable right for such set off. Deferred tax assets are reviewed at each Balance Sheet date for their realisability. Since there are no virtual certainty with convincing evidence that there will be sufficient future taxable income against which it can be realised, deferred tax asset/liability is not recognised during the year."



GENLINK PHARMA SOLUTIONS PRIVATE LIMITED
 (Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)
Notes forming part of Financial Statements for the year ended 31st December 2022

Note 3 : NON CURRENT INVESTMENTS

Particulars	As at	As at	As at	As at
	31st Dec 2022	30 Sept 2022 (Unaudited)	30 June 2022 (Unaudited)	31 March 2022 (Audited)
	Rs.	Rs.	Rs.	Rs.
(a) In Equity Instruments (Unquoted)				
(i) In Associate Company				
- Enaltec Labs Private Limited				
- 563497 Equity Shares (PY - 563497), fully paid up	24,89,95,479	24,89,95,479	24,89,95,479	24,89,95,479
Equity shares were pledged with the debenture trustee as a security for issuance of Zero Coupon, Secured, Redeemable, Non-Convertible Debentures. Refer note to schedule 10 on default in repayment of debt on maturity.				
Total	24,89,95,479	24,89,95,479	24,89,95,479	24,89,95,479

Note 4 : TRADE RECEIVABLE

Particulars	As at	As at	As at	As at
	31st Dec 2022	30 Sept 2022 (Unaudited)	30 June 2022 (Unaudited)	31 March 2022 (Audited)
	Rs.	Rs.	Rs.	Rs.
Trade receivable - more than 6 months				
Trade receivable - less than 6 months				26,254
Less: Provision for doubtful debts				
Total				26,254

Particulars	31/12/2022					Total
	Outstanding for following periods from due date of payment#					
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More Than 3 years	
(i) Undisputed Trade receivables – considered good						
(ii) Undisputed Trade Receivables – considered doubtful						
(iii) Disputed Trade Receivables considered good						
(iv) Disputed Trade Receivables considered doubtful						

Particulars	31/03/2022					Total
	Outstanding for following periods from due date of payment#					
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More Than 3 years	
(i) Undisputed Trade receivables – considered good						
(ii) Undisputed Trade Receivables – considered doubtful						
(iii) Disputed Trade Receivables considered good						
(iv) Disputed Trade Receivables considered doubtful						



GENLINK PHARMA SOLUTIONS PRIVATE LIMITED
(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)
Notes forming part of Financial Statements for the year ended 31st December 2022

Note 5 : CASH AND CASH EQUIVALENTS

Particulars	As at 31st Dec 2022	As at 30 Sept 2022 (Unaudited)	As at 30 June 2022 (Unaudited)	As at 31 March 2022 (Audited)
	Rs.	Rs.	Rs.	Rs.
(a) Balances with banks	16,256	3,326	14,095	57,43,742.87
(b) Cash on hand	67	67	67	67.00
Total	16,323	3,393	14,162	57,43,809.87

Note 6 : LOANS

Particulars	As at 31st Dec 2022	As at 30 Sept 2022 (Unaudited)	As at 30 June 2022 (Unaudited)	As at 31 March 2022 (Audited)
	Rs.	Rs.	Rs.	Rs.
Loan to related parties	47,02,686	50,38,000	53,65,881	-
Total	47,02,686	50,38,000	53,65,881	-

Note 7 : Other Current Assets

Particulars	As at 31st Dec 2022	As at 30 Sept 2022 (Unaudited)	As at 30 June 2022 (Unaudited)	As at 31 March 2022 (Audited)
	Rs.	Rs.	Rs.	Rs.
Prepaid Expenses	78,719	93,219	63,579	79,064.00
Deposit with BSE	25,000	25,000	25,000	25,000.00
Advance tax (Net)	5,72,875	5,27,997	4,78,151	4,27,981.00
Interest accrued on loan	82,526	6,82,308	6,36,937	6,00,443.00
MAT Credit	2,568	2,568	2,568	2,568.00
Advances to suppliers	-	9,735	88,500	-
Balance with govt authorities	-	-	-	-
Total	7,61,688	13,40,827	12,94,735	11,35,056.00

Note 8 : SHARE CAPITAL

Particulars	As at 31st Dec 2022	As at 30 Sept 2022 (Unaudited)	As at 30 June 2022 (Unaudited)	As at 31 March 2022 (Audited)
	Rs.	Rs.	Rs.	Rs.
Authorised 10,000 Ordinary Shares of Rs. 10/- each	1,00,000	1,00,000	1,00,000	1,00,000.00
Issued 10,000 Ordinary Shares of Rs. 10/- each	1,00,000	1,00,000	1,00,000	1,00,000.00
Subscribed & Paid up 10,000 Ordinary Shares of Rs. 10/- each	1,00,000	1,00,000	1,00,000	1,00,000.00
Total	1,00,000	1,00,000	1,00,000	1,00,000.00

Additional Information:

(1) Movement in subscribed and paid up share capital

Ordinary shares of Rs. 10 each	As at 31st Dec 2022		As at 31 March 2022 (Audited)	
	No of Shares	Rs.	No of Shares	Rs.
At the beginning of the year	10,000	1,00,000	10,000	1,00,000
Shares allotted during the period	-	-	-	-
Shares converted during the period	-	-	-	-
At the end of the year	10,000	1,00,000	10,000	1,00,000

(2) Right, Powers and Preferences

- (a) The Company has only one class of shares referred to as Equity Shares having a par value of Rs 10/-.
(b) Each holder of Equity shares is entitled to one vote per share.
(c) In the event of liquidation, shareholders of Ordinary shares are eligible to receive the remaining assets of the company after distribution of all preferential amounts, in proportion to their shareholding.

(3) Shareholders holding more than 5% shares in the company

Name of Shareholders	As at 31st Dec 2022		As at 31 March 2022 (Audited)	
	No of Shares	%	No of Shares	%
EQUITY SHAREHOLDERS				
1 Mr. Anand Shah	5,000	50	5,000	50
2 Mr. Susheel Koul	5,000	50	5,000	50
Total	10,000	100.00	10,000	100

(4) Shareholding of Promoters

Promoter's Name	As at 31st Dec 2022		As at 31 March 2022 (Audited)		% Change during the year
	No of Shares	%	No of Shares	%	
1 Mr. Anand Shah	5,000	50.00	5,000	50	No Change
2 Mr. Susheel Koul	5,000	50.00	5,000	50	No Change
Total	10,000	100.00	10,000	100	



GENLINK PHARMA SOLUTIONS PRIVATE LIMITED
(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)
Notes forming part of Financial Statements for the year ended 31st December 2022

Note 9 : RESERVES & SURPLUS

Particulars	As at	As at	As at	As at
	31st Dec 2022	30 Sept 2022 (Unaudited)	30 June 2022 (Unaudited)	31 March 2022 (Audited)
	Rs.	Rs.	Rs.	Rs.
(a) Surplus				
Opening Balance				28,55,679.65
Add : Net Profit/(Loss) For the current period	44,42,119	38,98,696	38,98,696	10,43,016.05
Closing Balance	3,07,027	5,43,299	2,41,922	
	47,49,146	44,41,994	41,40,618	38,98,695.70
Total	47,49,146	44,41,994	41,40,618	38,98,695.70

Note 10 : LONG TERM BORROWINGS

Particulars	As at	As at	As at	As at
	31st Dec 2022	30 Sept 2022 (Unaudited)	30 June 2022 (Unaudited)	31 March 2022 (Audited)
	Rs.	Rs.	Rs.	Rs.
Secured Borrowings				
Zero Coupon, Secured Redeemable, Non Convertible Debentures				
Loan Agst Property	2,00,22,922	2,07,62,341	2,14,17,190	2,21,14,531.00
	2,00,22,922	2,07,62,341	2,14,17,190	2,21,14,531.00
Unsecured Borrowings				
Loan from Directors	20,00,000	20,00,000	20,00,000	20,00,000.00
	20,00,000	20,00,000	20,00,000	20,00,000.00
Total	2,20,22,922	2,27,62,341	2,34,17,190	2,41,14,531.00

Additional Information:

(1) Details of outstanding secured borrowings are as follows:

250 - Zero coupon, Non Convertible Debentures of Rs. 10 Lacs each aggregating to Rs. 2,500 Lacs, are secured by way of pledging 563497 Equity shares held by Genlink (PY - 563497 Equity shares) as non current investment by the company and 11846 shares held by Promoters (PY - 11846 Equity shares) of Fnaltec Labs Private Limited . Debentures are redeemable in full at premium of Rs. 12,71,515/- per debenture on 27.09.2021. As per Common Shareholders Agreement dated January 18, 2022, specifically clause 12 and sub clause 12.4, and as per waiver letters dated January 22, 2022 and February 2, 2022 the NCD holder viz. Riverstreet and the Debenture Trustee viz. Vistra ITCL (India) Ltd., respectively, have waived their rights under the Debenture Trust Deed dated March 17, 2017 and as per legal opinion dt.19.08.2022 and management clarification dt.20.08.2022 the management is of the opinion that no enforceable liability to pay premium of Rs.12,71,575/- per NCD on March 31, 2022. Based on this, we had not created any debenture premium in books till 30th June, 2022.



GENLINK PHARMA SOLUTIONS PRIVATE LIMITED
(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)
Notes forming part of Financial Statements for the year ended 31st December 2022

(2) Details of Current and non current maturities of Long term borrowings:

Particulars	01.04.2022 to 31.12.2022			2021-22		
	Non - Current	Current	Total	Non - Current	Current	Total
Secured Borrowing						
Zero Coupon, Secured Redeemable, Non Convertible Debentures (Refer Note above)		25,00,00,000	25,00,00,000		25,00,00,000	25,00,00,000
Loan Agst Property	2,00,22,922	27,84,483	2,28,07,405	2,21,14,531	26,62,881	2,47,77,412
Unsecured Loan						
Loan from Directors	20,00,000		20,00,000		20,00,000	20,00,000
	2,20,22,922	25,27,84,483	27,48,07,405	2,21,14,531	25,46,62,881	27,67,77,412

Note 11 : TRADE PAYABLE

Particulars	As at 31st Dec 2022	As at 30 Sept 2022 (Unaudited)	As at 30 June 2022 (Unaudited)	As at 31 March 2022 (Audited)
TRADE PAYABLE				
Sundry Creditors MSME				
Sundry Creditors other than MSME				
	3,11,040.00	1,59,640.00	81,178.00	77,576
TOTAL	3,11,040.00	1,59,640.00	81,178.00	77,576

Particulars	31/12/2022				
	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME					
(ii) Others	2,29,862	80640			
(iii) Disputed Dues - MSME				538	3,11,040.00
(iv) Disputed Dues -Others					
Total					3,11,040.00

Note 12 : OTHER FINANCIAL LIABILITIES

Particulars	As at 31st Dec 2022	As at 30 Sept 2022 (Unaudited)	As at 30 June 2022 (Unaudited)	As at 31 March 2022 (Audited)
	Rs.	Rs.	Rs.	Rs.
(a) TDS Payable		360	1,000	10,920
(b) GST Payable				43,674
(c) Interest Payable on Unsecured Loans	94,305	40,080	60,839	13,29,159
(c) Advance from customers	7,75,824	7,75,824	7,75,824	
(d) Deposit for rent	19,350	8,45,348	10,16,207	
(e) Capital Creditors	17,50,000	17,50,000	17,50,000	17,50,000
Total	26,39,479	34,11,612	36,03,870	31,33,753

Note 13 : SHORT TERM BORROWINGS

Particulars	As at 31st Dec 2022	As at 30 Sept 2022 (Unaudited)	As at 30 June 2022 (Unaudited)	As at 31 March 2022 (Audited)
	Rs.	Rs.	Rs.	Rs.
(a) Current Maturities of long term debt*	25,27,84,483	25,27,18,967	25,27,84,483	25,46,62,881
Total	25,27,84,483	25,27,18,967	25,27,84,483	25,46,62,881

Note 14 : PROVISIONS

Particulars	As at 31st Dec 2022			As at 30 Sept 2022 (Unaudited)			As at 31 March 2022 (Audited)		
	Long Term	Short Term	Total	Long Term	Short Term	Total	Long Term	Short Term	Total
Provision for expenses		3,63,500	3,63,500		4,12,750	4,12,750		2,57,500	2,57,500
Total		3,63,500	3,63,500		4,12,750	4,12,750		2,57,500	2,57,500

Note 15 : OTHER CURRENT LIABILITY

Particulars	As at 31st Dec 2022	As at 30 Sept 2022 (Unaudited)	As at 30 June 2022 (Unaudited)	As at 31 March 2022 (Audited)
Advance received from customer				5,27,379
TOTAL				5,27,379



GENLINK PHARMA SOLUTIONS PRIVATE LIMITED
(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Notes forming part of Financial Statements for the year ended 31st December 2022

Note 16 : REVENUE FROM OPERATIONS

Particulars	For the quarter ended 31st Dec 2022 (Unaudited)	For the H1 ended 30 Sept 2022 (Unaudited)	For the quarter ended 30 Sept 2022 (Unaudited)	For the quarter ended 30 June 2022 (Unaudited)	For the year ended 31 March 22 (Audited)
	Rs.	Rs.	Rs.	Rs.	Rs.
Service Income					
Rent Income	10,89,000	21,78,000	10,89,000	10,89,000	40,92,000
Total	10,89,000	21,78,000	10,89,000	10,89,000	40,92,000

Note 17 : OTHER INCOME

Particulars	For the quarter ended 31st Dec 2022 (Unaudited)	For the H1 ended 30 Sept 2022 (Unaudited)	For the quarter ended 30 Sept 2022 (Unaudited)	For the quarter ended 30 June 2022 (Unaudited)	For the year ended 31 March 22 (Audited)
	Rs.	Rs.	Rs.	Rs.	Rs.
Interest Income on loans	95,936	2,08,055	1,18,656	89,399	5,34,311
Interest Income on Income tax refunds					22,754
Sundry provision write off		538	538		25,000
Total	95,936	2,08,593	1,19,194	89,399	5,82,065

Note 18 : FINANCE COST

Particulars	For the quarter ended 31st Dec 2022 (Unaudited)	For the H1 ended 30 Sept 2022 (Unaudited)	For the quarter ended 30 Sept 2022 (Unaudited)	For the quarter ended 30 June 2022 (Unaudited)	For the year ended 31 March 22 (Audited)
	Rs.	Rs.	Rs.	Rs.	Rs.
Interest expense	4,83,436	10,18,839	5,02,769	5,16,070	21,44,364
Other Borrowing Cost	7,300	15,015	9,110	5,905	20,842
Premium on Redemption of NCD					
Total	4,90,736	10,33,854	5,11,879	5,21,975	21,65,206

Note 19 : DEPRECIATION & AMORTISATION EXPENSE

Particulars	For the quarter ended 31st Dec 2022 (Unaudited)	For the H1 ended 30 Sept 2022 (Unaudited)	For the quarter ended 30 Sept 2022 (Unaudited)	For the quarter ended 30 June 2022 (Unaudited)	For the year ended 31 March 22 (Audited)
	Rs.	Rs.	Rs.	Rs.	Rs.
Depreciation on tangible assets	1,35,212	2,68,365	1,35,212	1,33,153	5,11,443
Total	1,35,212	2,68,365	1,35,212	1,33,153	5,11,443

Note 20 : OTHER EXPENSES

Particulars	For the quarter ended 31st Dec 2022 (Unaudited)	For the H1 ended 30 Sept 2022 (Unaudited)	For the quarter ended 30 Sept 2022 (Unaudited)	For the quarter ended 30 June 2022 (Unaudited)	For the year ended 31 March 22 (Audited)
	Rs.	Rs.	Rs.	Rs.	Rs.
Depository Fees	18,750	75,000	18,750	56,250	37,500
Legal & Professional Fees	1,00,000	1,16,250	65,000	51,250	3,05,000
Rates & Taxes	1,314	5,287	4,196	1,091	-
Payment to Auditors (refer note below)	25,000	50,000	25,000	25,000	1,52,500
Insurance Charges	-	38,794	19,397	19,397	75,431
Website Exp	4,125	3,301	5,088	2,338	8,591
Listing Fees	2,125	8,500	(4,250)	8,500	8,500
Demat Account Maintenance Charges	18,750	56,250	18,750	37,500	84,200
ROC Charges	-	5,650	5,650	-	24,500
Advertisement Expenses	18,000	54,000	38,000	16,000	64,000
Miscellaneous Expenses					19,978
Total	1,88,064	4,13,032	1,95,581	2,17,326	7,80,200



GENLINK PHARMA SOLUTIONS PRIVATE LIMITED
(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)
Notes forming part of Financial Statements for the year ended 31st December 2022

(1) Payment to Auditors

Particulars	For the quarter ended 31st Dec 2022	For the quarter ended 30 Sept 2022	For the quarter ended 30 Sept 2022	For the quarter ended 30 June 2022 (Unaudited)	For the year ended 31 March 22 (Audited)
	Rs.	Rs.	Rs.	Rs.	Rs.
Payments to the auditor					
(a) Statutory audit fees	25,000	50,000	25,000	25,000	95,000
(b) Other services	-	-	-	-	57,500
Total	25,000	50,000	25,000	25,000	1,52,500



GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

DISCLOSURE UNDER REGULATION 52(4) OF SEBI (LODR), 2015

With reference to Regulation 52 (4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find disclosure as under for the quarter ended 31st December 2022.

1. Debt-equity ratio - **56.10** (in times)
2. Debt service coverage ratio - **0.26** (in times)
3. Interest service coverage ratio - **1.77** (in times)
4. Outstanding redeemable preference shares (quantity and value) - The Company does not have any outstanding redeemable preference shares.
5. Capital redemption reserve/debenture redemption reserve - **Nil**
6. Net worth - The net worth of the Company is **Rs 48.49 Lakhs**
7. Net profit after tax
Net profit after tax of the Company is **Rs. 8.50 Lakhs**
8. Earnings per share
Earnings per share of the Company is **Rs. 85.03.**
9. Current ratio - **0.02**
10. Long term debt to working capital -
11. Bad debts to Account receivable ratio - **NA**
12. Current liability ratio - **NA**
13. Total debts to total assets -
14. Debtors turnover - **NA**
15. Inventory turnover - **NA**



GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

16. Operating margin (%) - NA

17. Net profit margin (%) - 31.91



GENLINK PHARMA SOLUTIONS PRIVATE LIMITED


(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

STATEMENT OF VALUE OF PLEDGED SECURITIES AS ON YEAR ENDED 31ST DECEMBER 2022

We hereby state that the Company maintains as on 31st December 2022 such pledged securities as enlisted below:

1. 563,497 Equity Shares of Enaltec Labs Private Limited held by Genlink Pharma Solutions Private Limited at value of Rs. Nil per share vide Valuation Report by Vira Financial Advisors Private Limited aggregating to Rs. Nil.
2. 5,923 Equity Shares of Enaltec Labs Private Limited held by Mr. Anand Shah at value of Rs. Nil per share vide Valuation Report by Vira Financial Advisors Private Limited aggregating to Rs. Nil.
3. 5,923 Equity Shares of Enaltec Labs Private Limited held by Mr. Susheel Koul at value of Rs. Nil per share vide Valuation Report by Vira Financial Advisors Private Limited aggregating to Rs. Nil.

For Genlink Pharma Solutions Private Limited



Anand Shah
Director
DIN: 00597145



Date: 12/09/2023
Place: Navi Mumbai

Shankarlal Jain & Associates LLP

Chartered Accountants



12, Engineer Building, 265 Princess Street, Mumbai - 400 002. India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

To,


Stock Exchange (s)

As per requirement of SEBI circular no. SEBI/HO/MIRSD/MIRSD_CRADT/CIR/P/2022/67 dated May 19, 2022 & based on examination of books of accounts and other relevant records/documents of **M/s. GENLINK PHARMA SOLUTIONS PRIVATE LIMITED**, (CIN: U74110MH2016PTC280765) for **quarter ending on 31st December 2022 (unaudited)**, having its registered office at 1701, 17th Floor, Kesar Solitaire, Plot No 5, Sector 19, Sanpada, Navi Mumbai – 400 705, Maharashtra, India, we hereby certify security cover certificate given below.

Security Cover Certificate for listed debt securities

As per Regulation 54 read with regulation 56 (1) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with aforementioned circular no.

Sr. No.	Particulars	Amount
I.	Assets available for secured Debt Securities' – (secured by either pari passu or exclusive charge on assets) (refer note below)	Nil
	<ul style="list-style-type: none">Property Plant & EquipmentCapital Work in ProgressRight of use AssetsGood Will	Nil
	<ul style="list-style-type: none">Intangible AssetsIntangible Assets under developmentInvestmentsLoansInventoriesTrade ReceivablesCash & Cash EquivalentsBank balances other than Cash & Cash EquivalentsOthers	Nil



Shankarlal Jain & Associates LLP

Chartered Accountants



12, Engineer Building, 265 Princess Street, Mumbai - 400 002, India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

ii	Liabilities for secured Debt Securities' – (secured by either pari passu or exclusive charge on assets) (refer note below)	25.00 crore
	<ul style="list-style-type: none">Debt Securities to which this certificate pertainsOther debt sharing pari-passu charge with above debtOther debtSubordinated debtBorrowingsBankDebt securitiesOthersTrade PayablesLease LiabilitiesProvisionsOthers	25.00 crore Nil
iii	<ul style="list-style-type: none">Exclusive Security Cover Ratio (Value of Assets having exclusive charge / Outstanding Value of corresponding debt + Interest Accrued) (refer note below) (Nil /25 cr)	Nil
iv	<ul style="list-style-type: none">Pari – Passu Security Cover Ratio	N.A.

Note 1: The **debt is secured** against 5,63,497 Equity Shares of Enaltec Labs Private Limited Cost of which is Rs. 24.89 Crores, as per valuation report dated 01.12.2021, the **present market value for Assets charged on exclusive basis is NIL.**

Note 2: As per Common Shareholders Agreement dated January 18, 2022, specifically clause 12 and sub clause 12.4, and as per waiver letters dated January 22, 2022 and February 2, 2022 the NCD holder viz. River street and the Debenture Trustee viz. Vistra ITCL (India) Ltd., respectively, have waived their rights under the Debenture Trust Deed dated March 17, 2017 and as per **legal opinion dt.28.08.2023** and management clarification dt.30.11.2022 the management is of the opinion that no enforceable liability to pay premium of Rs.12,71,575/- per NCD upto 31st December 2022. Accordingly, NCD shall now be redeemed at future date and the premium shall be computed based on the valuation of the underlying pledge shares. Since the value is not determinable today, hence are contingent in nature and not considered.

FOR SHANKARLAL JAIN & ASSOCIATES LLP
CHARTARED ACCOUNTATS
FIRM REG NO. 109901W/W100082

Satish Jain

SATISH JAIN
Partner

Membership No. 048874
UDIN: 3048874BGTMGK8110



Place: Mumbai
Date 11/09/2023